Quiver Bioscience, a discovery technology and therapeutics company advancing programs for the treatment of serious central nervous system (CNS) disorders, announced a targeted investment from the Porta family. (Argentina) office to advance its antisense oligonucleotide (ASO) therapeutic program for chromosome 15q duplication (Dup15q) syndrome. The investment will fund preclinical activities essential to the program, including safety studies for development candidate selection on the path toward clinical development.